Nexalin Technology, Inc. (NASDAQ:NXL) Short Interest Update

by · The Markets Daily

Nexalin Technology, Inc. (NASDAQ:NXL – Get Free Report) saw a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 320,400 shares, a decrease of 34.7% from the December 15th total of 491,000 shares. Approximately 3.1% of the shares of the company are short sold. Based on an average daily volume of 1,730,000 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Nexalin Technology in a report on Thursday, December 5th.

Check Out Our Latest Research Report on NXL

Nexalin Technology Stock Performance

Nexalin Technology stock opened at $2.51 on Tuesday. Nexalin Technology has a one year low of $0.25 and a one year high of $4.49. The company has a 50-day simple moving average of $3.51 and a 200-day simple moving average of $1.98. The firm has a market capitalization of $33.39 million, a P/E ratio of -3.92 and a beta of 4.24.

Nexalin Technology (NASDAQ:NXL – Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.04 million during the quarter. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%.

Institutional Trading of Nexalin Technology

An institutional investor recently bought a new position in Nexalin Technology stock. CVI Holdings LLC purchased a new stake in shares of Nexalin Technology, Inc. (NASDAQ:NXL – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 55,462 shares of the company’s stock, valued at approximately $94,000. CVI Holdings LLC owned 0.52% of Nexalin Technology as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.65% of the company’s stock.

About Nexalin Technology

(Get Free Report)

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.

Featured Articles